Our focus is on research, acquisition, development, licensing, and marketing of
pharmaceutical products but we benefit from being part of a global family of specialists.
Each division can utilise the experience of the Kowa Company, Ltd. network to ensure
that processes are streamlined and constantly evolving to meet the needs of all
Livazo®/Livalo® pitavastatin is a fully synthetic and highly potent statin available across Asia, Europe, Latin America and North
America. It is indicated for the reduction of elevated total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) in adult patients with
primary hypercholesterolemia, including heterozygous familial hypercholesterolemia, and combined (mixed) dyslipidemia, when response to dietary and other
non-pharmacological measures are inadequate.1
Since its 2003 launch in Japan, pitavastatin has accumulated millions of patient-years of exposure2 and has confirmed its place in the statin
armamentarium, particularly for patients who require high-density lipoprotein cholesterol (HDL-C) raising or where poly-pharmacy exists, with a risk of
drug-to-drug interactions. More recently, a study conducted in Japan demonstrated that pitavastatin did not increase the risk of developing diabetes in a
large group of patients with impaired glucose tolerance.3
Pitavastatin is marketed in several European countries by our partner Recordati (primarily under the Livazo® brand name). For more
information on ordering pitavastatin or for patient materials, please get in touch with our partners.
Find out more about our partnerships.